Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Building a Culture of Passion and Commitment

November 18, 2019

I joined Alnylam in May 2019, which makes me a newcomer relative to three quarters of our organization. However, having developed my career in the healthcare space over the last 20 years, I’ve watched Alnylam grow, and create a unique culture that appeals to very talented, high-performing, mission-driven people. Our culture, which was founded on passion for excellence, innovation and discovery in science, commitment to people, openness, and sense of urgency, has served us incredibly well for over 17 years. What's truly remarkable to me is that Alnylam has maintained this level of commitment to our people and focus on our culture which landed us on the Boston Globe’s Top Places to Work list for the fifth year in a row – all while driving rapid, global growth which is often when many cultures lose their way.

In the past five years, as we’ve worked to bring our first medicines to market and further develop our deep pipeline, we’ve added over 1,000 employees and expanded globally with operations in 16 countries. We now have Alnylam employees working out of more than 25 offices – and many who work remotely or are field based  – all who come from diverse backgrounds.

What's truly remarkable to me is that Alnylam has maintained this level of commitment to our people and focus on our culture which landed us on the Boston Globe’s Top Places to Work list for the fifth year in a row – all while driving rapid, global growth which is often when many cultures lose their way.

So, what makes a company a “best place to work?” To me, it’s when employees are deeply inspired by their company’s mission, knowing that they play a key role in the organization’s purpose and feel valued for their impact. Our employees have always taken very personally the opportunity – and responsibility – to help patients with devastating diseases. Taking on this shared mission is serious and often hard work, but we also laugh a lot and have fun, even in the toughest of times. I think that’s possible because, deep down, we know that our colleagues around the table are committed to our mission to impact patients lives and are committed to each other as people. Alnylam is also a place where we are expected to bring our whole selves to work and are appreciated for our differences. Our commitment to building a diverse and inclusive workplace is not lip-service – it’s ingrained in the very fabric of our company and our culture. Even during my initial interviews, it was clear that Alnylam embraced this spirit of honesty and authenticity.

Our open culture is important now more than ever as Alnylam continues to grow as an organization not only in number but in the types of people we attract. Within the past two years alone, the composition of Alnylam’s employees has shifted dramatically as we’ve added patient services, commercial and manufacturing functions alongside our R&D teams. Not many biotech companies make it to this stage, so for me, it’s this confluence of people and distinctive perspectives that makes it a very exciting time to be here, building the future of Alnylam.  

Kelley Boucher is Alnylam's Chief Human Resources Officer

It’s also critically important as we grow and our employee population changes, that we stay in tune with what employees need and want so we make it a priority to listen. Like many other high-performing organizations, we conduct an annual culture survey to evaluate our successes and challenges. Translating those insights into tangible actions to benefit our employees and the company overall is the greatest challenge. Of course, ranking well on these type of lists is not the ultimate goal, but surveys like these provide us another opportunity to learn from our people and ensure we stay ahead what’s important to them.

This year, similar to most years, our employees rated us highest on the  attributes that have shaped Alnylam since day one: our mission, our vision, and our commitment to patients and each other Many companies can say they’ve been named a “Top Places to Work” once or even a few times, and it’s always an achievement to celebrate and be proud of. The fact that we have been named consistently for five years tells me that we're doing well by our people, that our hearts are in the right place, and that our mission and values continue to resonate with our colleagues who agree with me, that Alnylam is a truly special place to be.

Tags

Careers & Culture, Articles, Boston Globe Top Places to Work, Awards, Executive Team

Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site